CLEC12A and B-cell chronic lymphocytic leukemia: Along similar lines, Tashiro et al. described the development and evaluation of CLL-1-specific chimeric antigen receptor T cells (CLL-1.CAR-Ts) and further demonstrated their specific activity against CLL-1+ AML cell lines as well as primary AML patient samples in vitro.